Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime.

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime.

Human immunodeficiency virus (HIV) vaccine candidates were previously constructed as a string of cytotoxic T lymphocyte (CTL) epitopes delivered and expressed using DNA and modified virus Ankara (MVA; an attenuated vaccinia virus) vectors. These vaccines were shown to induce interferon (IFN)-gamma-p...

Full description

Bibliographic Details
Main Authors:	Hanke, T, Blanchard, T, Schneider, J, Hannan, C, Becker, M, Gilbert, S, Hill, A, Smith, G, McMichael, A
Format:	Journal article
Language:	English
Published:	1998

Similar Items

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
by: Gilbert, S, et al.
Published: (2006)

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS.
by: Hanke, T, et al.
Published: (1999)

Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use.
by: Plebanski, M, et al.
Published: (1998)

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.
by: Nkolola, J, et al.
Published: (2004)

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies.
by: Schneider, J, et al.
Published: (1999)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
by: Schneider, J, et al.
Published: (1998)

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
by: Dunachie, S, et al.
Published: (2006)

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.
by: Gilbert, S, et al.
Published: (2002)

Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime.
by: Hanke, T, et al.
Published: (1999)

Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope.
by: Gotch, F, et al.
Published: (1993)

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice
by: Georgia Kalodimou, et al.
Published: (2023-05-01)

Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults
by: Rampling, T, et al.
Published: (2015)

Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
by: Hanke, T, et al.
Published: (1999)

HETEROLOGOUS PRIME-BOOST VACCINATION WITH ADCH63 AND MVA EXPRESSING MSP1 CAN INDUCE PROTECTIVE EFFICACY AGAINST SPOROZOITE CHALLENGE IN VOLUNTEERS
by: Sheehy, S, et al.
Published: (2010)

Construction of MHC class I-peptide tetrameric complexes for analysis of T-cell-mediated immune responses.
by: Samuel, R, et al.
Published: (2003)

A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
by: Ewer (nee Russell), K, et al.
Published: (2016)

A DNA Prime and MVA Boost Strategy Provides a Robust Immunity against Infectious Bronchitis Virus in Chickens
by: Shaswath S. Chandrasekar, et al.
Published: (2023-01-01)

T-cell strategies in AIDS vaccines: MHC-restricted T-cell responses to HIV proteins.
by: Mills, K, et al.
Published: (1989)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
by: Kimani, D, et al.
Published: (2014)

INTERACTIONS BETWEEN PEPTIDE AND CLASS-I MHC - IMPLICATIONS FOR IMMUNOTHERAPY IN RHEUMATIC DISEASE
by: Moots, R, et al.
Published: (1993)

INTERACTIONS BETWEEN PEPTIDE AND CLASS-I MHC - IMPLICATIONS FOR IMMUNOTHERAPY IN RHEUMATIC DISEASE
by: Moots, R, et al.
Published: (1993)

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques
by: Rosario, M, et al.
Published: (2012)

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.
by: Rosario, M, et al.
Published: (2012)

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
by: Swadling, L, et al.
Published: (2014)

Functions of nonclassical MHC and non-MHC-encoded class I molecules.
by: Braud, V, et al.
Published: (1999)

DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.
by: Hill, A, et al.
Published: (2000)

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
by: Im, E, et al.
Published: (2006)

Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen.
by: Larke, N, et al.
Published: (2005)

Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice
by: Ann-Sophie Stephan, et al.
Published: (2023-01-01)

Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming.
by: Plebanski, M, et al.
Published: (1999)

Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.
by: Hanke, T
Published: (2014)

MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans
by: Cunha-Neto E.
Published: (1999-01-01)

Development of a DNA-MVA/HIVA vaccine for Kenya.
by: Hanke, T, et al.
Published: (2002)

Prime-boost immunisation strategies for tuberculosis.
by: Mcshane, H, et al.
Published: (2005)

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
by: Schneider, J, et al.
Published: (2001)

Characterisation of antigenic MHC Class I-restricted T cell epitopes in the glycoprotein of Ebolavirus
by: Powlson, J, et al.
Published: (2019)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
by: Sheehan, S, et al.
Published: (2015)

NATURE OF MHC RESTRICTIONS IN T-B COOPERATION
by: Waldmann, H, et al.
Published: (1978)

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses
by: Alex Olvera, et al.
Published: (2024-03-01)

IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations
by: María Paula Morelli, et al.
Published: (2020-09-01)